Close Menu

NEW YORK – Vividion Therapeutics said on Wednesday it has raised $135 million in a Series C financing round led by two new investors, Logos Capital and Boxer Capital of Tavistock Group.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.